Smoothies and Blood Sugars

September 12, 2024 updated by: Javier Gonzalez, University of Bath

Examining the Blood Sugar Response to Fruit Smoothie Consumption

Glycaemic responses to fruit smoothies may depend on the food matrix (e.g., degree of processing and physical structure), ingestion rate, dose ingested and fibre content. Furthermore, the method of sampling could alter inferences. The aim of this project is to characterise how these factors affect the glycaemic response to a commercially available fruit smoothie. Participants will ingest 7 different test drinks in a randomised, crossover design with fingerstick capillary blood sampling alongside continuous glucose monitors. Test drinks will include a glucose reference (CONTROL), the commercial product matched for carbohydrate to CONTROL (PRODUCT), equivalent carbohydrate ingested as whole fruits (WHOLE), equivalent carbohydrate ingested as blended fruits (WHOLE), equivalent carbohydrate as the commercial product ingested slowly (SLOW), equivalent carbohydrate as the commercial product ingested with additional fibre (FIBRE), and the commercial product ingested in a dose typically bought (DOSE). These data will provide insight into how the food matrix and different patterns of ingestion can alter the glycaemic response to a fruit smoothie, and how the measurement method may alter interpretations.

Study Overview

Status

Completed

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

15

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Bath, United Kingdom, BA2 7AY
        • Department for Health, University of Bath

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Age: 18-65 years
  • Body mass index 18-30 kg/m2

Exclusion Criteria:

  • diagnosis of any form of diabetes
  • intolerances or allergies to any of the study procedures (e.g. fructose/inulin intolerance)
  • Fructose malabsorption
  • Inborn errors of fructose metabolism (e.g. fructokinase deficiency, aldolase B deficiency, fructose-1,6-bisphosphatase deficiency)
  • pregnant or lactating
  • any condition that could introduce bias to the study (e.g. diagnoses of lipid disorders, including cardiovascular disease, or therapies that alter lipid or glucose metabolism, such as statins or niacin).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Control
50 g glucose (55 g dextrose powder accounting for hydration) plus 417 mL water
Fruit ingested in whole form or as either commercially available, or home-made smoothies
Experimental: Product
417 mL of commercially available "Mango & Passion fruit" fruit smoothie providing 50 g carbohydrate
Fruit ingested in whole form or as either commercially available, or home-made smoothies
Experimental: Whole
Apples (51%), Mango (16%), Banana (16%), Orange (12%), Passionfruit (3%), Peach (2%), Lime (0.4%; recipe matched to PRODUCT) eaten as whole fruit with added water as needed to match volume.
Fruit ingested in whole form or as either commercially available, or home-made smoothies
Experimental: Blend
Apples (51%), Mango (16%), Banana (16%), Orange (12%), Passionfruit (3%), Peach (2%), Lime (0.4%; recipe matched to PRODUCT) eaten as blended fruit with added water as needed to match volume.
Fruit ingested in whole form or as either commercially available, or home-made smoothies
Experimental: Slow
417 mL of commercially available "Mango and Passionfruit" fruit smoothie providing 50 g carbohydrate ingested slowly over 25-35 mins.
Fruit ingested in whole form or as either commercially available, or home-made smoothies
Experimental: Fibre
417 mL of commercially available "Mango and Passionfruit" fruit smoothie providing 50 g carbohydrate with 6 g of added inulin.
Fruit ingested in whole form or as either commercially available, or home-made smoothies
Experimental: Dose
250 mL of commercially available "Mango and Passionfruit" fruit smoothie providing 30 g carbohydrate.
Fruit ingested in whole form or as either commercially available, or home-made smoothies

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Glycaemic index of product with capillary vs CGM
Time Frame: 120 min
The difference in glycaemic index [2-hour incremental area under the curve (mmol/L-1x120 min) for PRODUCT relative to CONTROL expressed as a percentage] in capillary blood samples versus continuous glucose monitors.
120 min

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Glycaemic index of all conditions with capillary vs CGM
Time Frame: 120 min
The difference in glycaemic index [2-hour incremental area under the curve (mmol/L-1x120 min) for all other conditions (WHOLE, BLEND, SLOW, FIBRE, DOSE) relative to CONTROL expressed as a percentage] in capillary blood samples versus continuous glucose monitors.
120 min

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Condition-by-sampling interaction
Time Frame: 120 min
The effect of condition-by-blood sampling (capillary vs continuous glucose monitor) interaction for the 2-hour incremental area under the curve for all conditions.
120 min
GI of products in capillary samples
Time Frame: 120 min
Comparisons between conditions for the 2-hour incremental area under the curve relative to CONTROL using capillary blood glucose.
120 min
GI of products in continuous glucose monitors
Time Frame: 120 min
Comparisons between conditions for the 2-hour incremental area under the curve relative to CONTROL using continuous glucose monitors.
120 min
Peak glucose capillary vs CGM
Time Frame: 120 min
The condition-by-blood sampling interaction for the postprandial peak glucose concentrations (mmol/L)
120 min
Time to peak glucose capillary vs CGM
Time Frame: 120 min
The condition-by-blood sampling interaction for the time to peak glucose concentrations (min)
120 min

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 20, 2024

Primary Completion (Actual)

August 30, 2024

Study Completion (Actual)

August 30, 2024

Study Registration Dates

First Submitted

March 20, 2024

First Submitted That Met QC Criteria

March 20, 2024

First Posted (Actual)

March 27, 2024

Study Record Updates

Last Update Posted (Actual)

September 19, 2024

Last Update Submitted That Met QC Criteria

September 12, 2024

Last Verified

September 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • 3085-4215

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

De-identified data will be made available open access on the University of Bath Research Data Archive (RDA) at the point of publication in a peer-reviewed journal.

IPD Sharing Time Frame

These will become available at the point of publication permanently.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Metabolic Disturbance

Clinical Trials on Food

Subscribe